References
- Pirlamarla P, Bond RM. FDA labeling of NSAIDs: review of nonsteroidal anti-inflammatory drugs in cardiovascular disease. Trends Cardiovasc Med 2016;26:675-680. https://doi.org/10.1016/j.tcm.2016.04.011
- Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from ran-domised trials. Lancet 2013;382:769-779. https://doi.org/10.1016/S0140-6736(13)60900-9
- Bell AD, Roussin A, Cartier R, Chan WS, Douketis JD, Gupta A, Kraw ME, Lindsay TF, Love MP, Pannu N, Rabasa-Lhoret R, Shuaib A, Teal P, Theroux P, Turpie AG, Welsh RC, Tanguay JF; Canadian Cardiovascular Society. The use of antiplatelet therapy in the outpatient setting: Canadian Car-diovascular Society guidelines. Can J Cardiol 2011;27 Suppl A:S1-S59. https://doi.org/10.1016/j.cjca.2010.12.015
- Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflam-matory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013;15 Suppl 3:S3.
- Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemor-rhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-1670. https://doi.org/10.1001/archinte.1993.00410140047006
- Chi TY, Zhu HM, Zhang M. Risk factors associated with nonsteroidal anti-inflammatory drugs (NSAIDs)-induced gas-trointestinal bleeding resulting on people over 60 years old in Beijing. Medicine (Baltimore) 2018;97:e0665. https://doi.org/10.1097/MD.0000000000010665
- Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical pic-ture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010;39:433-464. https://doi.org/10.1016/j.gtc.2010.08.010
- Lee W, Suh JW, Yang HM, Kwon DA, Cho HJ, Kang HJ, Kim HS, Oh BH. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J 2010;40:321-327. https://doi.org/10.4070/kcj.2010.40.7.321
- Li S, Liu B, Luo W, Zhang Y, Li H, Huang D, Zhou Y. Role of cyclooxygenase-1 and -2 in endothelium-dependent contrac-tion of atherosclerotic mouse abdominal aortas. Clin Exp Pharmacol Physiol 2016;43:67-74. https://doi.org/10.1111/1440-1681.12501
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Kon-stam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemopre-vention trial. N Engl J Med 2005;352:1092-1102. https://doi.org/10.1056/NEJMoa050493
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investiga-tors. Cardiovascular risk associated with celecoxib in a clini-cal trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080. https://doi.org/10.1056/NEJMoa050405
- Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-895. https://doi.org/10.1056/NEJMoa061652
- ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33. https://doi.org/10.1371/journal.pctr.0010033
- White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclo-fenac. Am J Cardiol 2002;89:425-430. https://doi.org/10.1016/S0002-9149(01)02265-2
- Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-1781. https://doi.org/10.1016/S0140-6736(06)69666-9
- Cho SK, Kim D, Won S, Lee J, Park B, Jang EJ, Bae SC, Sung YK. Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis. Semin Arth-ritis Rheum 2018;47:501-506. https://doi.org/10.1016/j.semarthrit.2017.08.002
- Chen YR, Hsieh FI, Chang CC, Chi NF, Wu HC, Chiou HY. Effect on risk of stroke and acute myocardial infarction of nonselective nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis. Am J Cardiol 2018;121:1271-1277. https://doi.org/10.1016/j.amjcard.2018.01.044
- Sica DS, Schoolwerth AC, Gehr TW. Pharmacotherapy in congestive heart failure: COX-2 inhibition: a cautionary note in congestive heart failure. Congest Heart Fail 2000;6:272-276. https://doi.org/10.1111/j.1527-5299.2000.80169.x
- Whelton A, Schulman G, Wallemark C, Drower EJ, Isak-son PC, Verburg KM, Geis GS. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-1470. https://doi.org/10.1001/archinte.160.10.1465
- Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006;70:1495-1502. https://doi.org/10.1038/sj.ki.5001766
- Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006;296:1619-1632. https://doi.org/10.1001/jama.296.13.jrv60015
- Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009;27:2332-2341. https://doi.org/10.1097/HJH.0b013e3283310dc9
- Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflam-matory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gas-troenterol Hepatol 2005;3:489-498. https://doi.org/10.1016/S1542-3565(04)00777-3
- Lapeyre-Mestre M, Grolleau S, Montastruc JL; Association Francaise des Centres Regionaux de Pharmacovigilance (CRPV). Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006. Fundam Clin Pharmacol 2013;27:223-230. https://doi.org/10.1111/j.1472-8206.2011.00991.x
- Bessone F, Hernandez N, Roma MG, Ridruejo E, Mendizabal M, Medina-Caliz I, Robles-Diaz M, Lucena MI, Andrade RJ. Hepatotoxicity induced by coxibs: how concerned should we be? Expert Opin Drug Saf 2016;15:1463-1475. https://doi.org/10.1080/14740338.2016.1225719
- Knowles S, Shapiro L, Shear NH. Should celecoxib be con-traindicated in patients who are allergic to sulfonamides? Revisiting the meaning of ‘sulfa’ allergy. Drug Saf 2001;24: 239-247. https://doi.org/10.2165/00002018-200124040-00001
- Lanza FL, Chan FK, Quigley EM; Practice Parameters Com- mittee of the American College of Gastroenterology. Guide-lines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-738. https://doi.org/10.1038/ajg.2009.115
- Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-664. https://doi.org/10.1136/gutjnl-2012-302084
- Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH; International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis: an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med 2015;13:55. https://doi.org/10.1186/s12916-015-0285-8
- Bruyere O, Cooper C, Pelletier JP, Maheu E, Rannou F, Branco J, Luisa Brandi M, Kanis JA, Altman RD, Hochberg MC, Martel-Pelletier J, Reginster JY. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-from evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016;45(4 Suppl):S3-S11. https://doi.org/10.1016/j.semarthrit.2015.11.010
Cited by
- Drug-induced nephrotoxicity vol.63, pp.1, 2018, https://doi.org/10.5124/jkma.2020.63.1.30
- 청피 물 추출물의 항염증 효과와 기전 연구 vol.34, pp.1, 2018, https://doi.org/10.15204/jkobgy.2021.34.1.034